Follow-up of intensive glucose control in type 2 diabetes [1]

New England Journal of Medicine

Volumn 360, Issue 4, 2009, Pages 416-418

  Lund, Søren S ^a   Rossing, Peter ^a   Vaag, Allan A ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

BLOOD GLUCOSE MONITORING; DIET RESTRICTION; FOLLOW UP; HUMAN; INTENSIVE CARE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT OUTCOME; DRUG COMBINATION; MORTALITY; NOTE; CAUSE OF DEATH; CLINICAL PRACTICE; BLOOD; GLUCOSE BLOOD LEVEL;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS; BLOOD GLUCOSE; INSULIN;

EID: 58749093747     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc082275     Document Type: Letter

References (3)

1. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-76.
2. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65. [Erratum, Lancet 1998;352:1558.]